OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT) Files An 8-K Other EventsItem 8.01 Other Events.
On January 2, 2018, Opiant Pharmaceuticals, Inc. issued a press release announcing that it received approximately $5.3 million of cash as a result of the exercise of a total of 356,790 warrants at prices of $10.00 and $15.00 per warrant by two individual investors. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description
OPIANT PHARMACEUTICALS, INC. ExhibitEX-99.1 2 opnt_receives5mfromwarrant.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding WarrantsSANTA MONICA,…To view the full exhibit click here
About OPIANT PHARMACEUTICALS, INC. (OTCMKTS:OPNT)
Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.
